
Medtronic Plc (NYSE:MDT) on Tuesday reported strong second-quarter 2026 results, with sales hitting $8.96 billion, surpassing the consensus estimate of $8.87 billion. This marks a 6.6% increase year-over-year, with organic growth of 5.5%.
Adjusted earnings of $1.36 per share also beat expectations of $1.31.